Indo Amines: 34% Profit CAGR + 11% Margins = The Quiet Chemical Kamehameha
1. At a Glance
Indo Amines is the introvert of the speciality chemical world. Doesn’t scream, doesn’t trend on FinTwit, and yet — delivers a 5-year profit CAGR of 34%, runs on double-digit margins, and just clocked its best-ever quarter. With a stock P/E of 15 and ROE of 19%, it’s like discovering your shy lab partner owns a meth lab (legal one) and makes more than the principal.
2. Introduction
While everyone chases mega-cap drama like Deepak Nitrite’s fluorine flames or Pidilite’s Fevicol monopoly, Indo Amines quietly runs a ₹1,100 crore operation pumping out niche chemicals for pharma, ink, fragrances, and even pesticides (no, not to kill investors).
The company has taken the slow-and-steady compounding route — no IPO drama, no 100x hype. And in Q1 FY26, it casually posted ₹29 Cr in profit, a 2x jump QoQ. That’s not “fine” chemicals. That’s damn refined.
But all’s not squeaky clean. Promoter stake has dropped from 69% to 58% in under 2 years. Dividend? ₹0.50 per share — enough to buy a stale samosa. Still, margins are improving, capacity is being added, and the stock trades at a steep discount to its sector peers. The risk-reward brew smells… complex.
3. Business Model (WTF Do They Even Do?)
Indo Amines manufactures speciality, fine, and performance chemicals used across:
Agrochemicals & Pharmaceuticals
High-performance polymers
Paints, printing inks, dyes, pigments
Fragrances, flavours, and surfactants
Rubber & Homecare formulations
This isn’t a “one formula fits all” game. Customers need customization, batch-to-batch consistency, and purity. So Indo doesn’t just sell a drum of chemicals — it sells process knowledge, long-term B2B relationships, and chemical credibility.
It has three main manufacturing facilities across Maharashtra and Gujarat, and a growing export book. Think of it as the Costco of custom chemicals — bulk buyers only, margins controlled by process efficiency, not by branding.
4. Financials Overview
Let’s toss the numbers into the cauldron and see what boils:
TTM Revenue: ₹1,101 Cr
EBITDA: ₹105 Cr → EBITDA Margin: ~9.5%
Net Profit: ₹66 Cr → PAT Margin: 6%
EPS (TTM): ₹9.11
P/E: 136 ÷ 9.11 = 14.9x
ROE: 19.3%
ROCE: 18.3%
Q1 FY26:
Revenue: ₹288 Cr
EBITDA: ₹31 Cr
Net Profit: ₹29 Cr
EPS: ₹3.97
Verdict? After two muted years, margins and profits are back in the lab coat. And this time, the results aren’t explosive — they’re surgical.
5. Valuation – Fair Value Range
Method
Calculation
Fair Value (₹)
P/E
EPS ₹9.11 × Sector Avg P/E ~18
164
EV/EBITDA
EV ₹1,059 Cr ÷ EBITDA ₹105 = 10.1x
155
DCF
18% profit CAGR, 10% discount rate
150
Fair Value Range: ₹150 – ₹165
“This FV range is for educational purposes only and is not investment advice.”
6. What’s Cooking – News, Triggers, Drama
Q1 FY26 Net Profit: ₹29 Cr — best in company history.
Dividend: ₹0.50/share. Not huge, but better than zero.
Cost Auditor Re-appointed: Nothing screams excitement like compliance.
